幽门螺杆菌人群筛查的成本效果:一项随机对照试验13年随访的经济学评价
在40-65岁一般人群中随机邀请20 011人,12 530人入组,8658人完成13年随访。幽门螺杆菌筛查与根除在生活质量方面无效,筛查者人均成本高于不筛查者(均值差11 269 DKK,95%CI 3175-19 362),每获得生命年支付意愿阈值为400 000 DKK时成本效果概率为80%。
要点
- 幽门螺杆菌人群筛查与根除在13年随访时对生活质量无效。
- 筛查者人均成本高于不筛查者,均值差11 269 DKK(95%CI 3175-19 362)。
- 每获得生命年支付意愿阈值400 000 DKK时成本效果概率为80%。
核心结论
- 幽门螺杆菌人群筛查与根除在13年随访时对生活质量无效,且筛查成本高于不筛查。
研究设计与样本
- 随机对照试验的经济学评价,包括成本效果分析和成本效用分析,随访13年,采用社会视角。
- 从40-65岁一般人群中随机抽取20 011人,于1998-1999年邀请,12 530人入组,8658人在干预后1、5、13年成功随访。
- 干预为邀请接受诊室血检幽门螺杆菌筛查,阳性者经13C-尿素呼气试验确认后接受根除治疗。
- 通过SF-36问卷衍生SF-6D评分计算质量调整生命年,并从登记数据获取所有随机个体的成本、医疗资源使用和用药数据。
主要发现
- 幽门螺杆菌人群筛查与根除在13年随访时对生活质量无效。
- 筛查者人均成本高于不筛查者,均值差11 269 DKK(95%CI 3175-19 362)。
- 每获得生命年支付意愿阈值为400 000 DKK(约53 800欧元)时,成本效果概率为80%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Helicobacter pylori eradication improves dyspeptic symptoms in 8%-10%, prevents peptic ulcer and may reduce the risk of gastric cancer. Availability of a high quality diagnostic test and an effective treatment makes population screening and eradication of Helicobacter pylori an attractive option. AIM: To evaluate the cost effectiveness of Helicobacter pylori population screening and eradication. METHODS: Cost effectiveness analysis and cost utility analysis alongside randomised controlled trial with 13 years follow-up. The evaluation has a societal perspective. A random general population sample of 20 011 individuals aged 40-65 were randomised and invited in 1998-1999; 12 530 were enrolled and, of these, 8658 have been successfully followed up at 1, 5, and 13 years after intervention. Questionnaires included the quality of life instrument SF-36. From SF-36 responses an SF-6D score was derived and used for calculation of quality-adjusted life years. Register data on costs, use of health care resources and medication were obtained for all randomised individuals. The intervention was an invitation to Helicobacter pylori screening by in-office blood test; positive tests were validated by 13 C-urea breath test. Those who tested positive were offered eradication therapy. Main outcome measures were Incremental cost per quality-adjusted life year and life-years gained. RESULTS: Helicobacter pylori population screening and eradication with 13 years follow-up was not effective in regards to quality of life and the cost per screened person was higher than not screening (mean difference 11 269 DKK [95% CI: 3175-19 362]). The probability of being cost-effective was 80% at a threshold of 400 000 DKK (approximately 53,800 Euros) of willingness-to-pay per life-year gained. CONCLUSIONS: Helicobacter pylori population screening and eradication with 13 years follow-up was not effective in regards to quality of life and the cost of screening was higher than not screening.
引用
- Høgh MB, Kronborg C, Hansen JM, et al. The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up. Aliment Pharmacol Ther. 2019. PMID: 30854700. doi:10.1111/apt.15193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。